A test of infection should not be a "standard" for guiding TB preventive therapy in at-risk populations

Int J Tuberc Lung Dis. 2022 Nov 1;26(11):1092-1093. doi: 10.5588/ijtld.22.0445.

Authors

J Furin¹, A Reuter², L Eyde³, H Cox⁴

Affiliations

¹ Harvard Medical School, Department of Global Health and Social Medicine, Boston, MA, USA.
² Médecins Sans Frontières, South Africa.
³ Treatment Action Group, New York, USA.
⁴ Institute of Infectious Disease and Molecular Medicine and Wellcome Centre for Infectious Disease Research, University of Cape Town, South Africa.

PMID: 36281036
DOI: 10.5588/ijtld.22.0445

No abstract available

Publication types

Letter
Comment

MeSH terms

Antitubercular Agents* / therapeutic use
Humans
Isoniazid
Tuberculin Test
Tuberculosis* / drug therapy
Tuberculosis* / prevention & control

Substances

Antitubercular Agents
Isoniazid